ClinicalTrials.gg

Neuralgia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,103 studies for Neuralgia across more than 10 countries. 243 are recruiting or about to start. 610 of them are mainly about Neuralgia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 5 narrower conditions too, such as Neuralgia, Postherpetic: 1,489 studies, 326 open.

ClinicalTrials.gov finds 1,978 studies for Neuralgia. How that becomes 1,098 here

This page counts the studies the registry files under Neuralgia, and those it files under no condition that list Neuralgiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,978Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −379Filed under a narrower condition, counted on its own pageNeuralgia, Postherpetic 144 · Sciatica 139 · Piriformis Muscle Syndrome 52 · Morton Neuroma 25 · Pudendal Neuralgia 16
  3. −207List Neuralgia as a condition, but the registry did not file them under itMost often written as “Trigeminal Neuralgia” (104), “Diabetic Neuropathic Pain” (9), and “Occipital Neuralgia” (9). The registry filed 2 of them under no condition at all, and the others under other conditions only, most often Trigeminal Neuralgia (121) and Pain (19).
  4. −294Match it another way220 name it in the title, 27 in a keyword, and 47 by a synonym or other text the search reads.
  5. 1,098The count on this page114 of them list Neuralgia in their own words; the registry filed them under no condition.

Status

Completed
586
Recruiting
154
Status unknown
114
Terminated
97
Not yet recruiting
72
Withdrawn
34

Phase

Phase 2
214
Phase 3
101
Phase 1
78
Phase 4
75
Early Phase 1
9

Where

United States
291
France
132
Turkey
79
Canada
70
United Kingdom
62
Denmark
53

Who develops what

Add Neuralgia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 16 companies, 14 with this as their studies’ main aim; 4 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Eli Lilly, Hypera Pharma and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PregabalinRecent, repeated
Evidence
  • NCT06628908 · Vertex Pharmaceuticals Incorporated · Phase 3 · live · comparator · “Pregabalin” · registered Sep 2024
  • NCT06619860 · Vertex Pharmaceuticals Incorporated · Phase 2 · live · comparator · “Pregabalin” · registered Sep 2024
  • NCT06221241 · Jemincare · Phase 2 · live · comparator · “Pregabalin” · registered Jan 2024
  • NCT05763550 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · comparator · “Pregabalin 150mg” · registered Feb 2023
  • NCT05324059 · laboratorios silanes s a de c v · Phase 3 · comparator · “Pregabalin 75mg” · registered Apr 2022
Viatris Inc.63% of its industry studiesUS: off-patent, 23 generics marketedEU: off-patent, 4 generics authorized45 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
suzetrigineApproved: US 2025☆ Track3 live phase-3 studies: NCT06696443, NCT06628908, NCT07231419Vertex Pharmaceuticals Incorporated
YJ001☆ Track1 live phase-3 study: NCT07859111Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Crisugabalin Besilate Capsules simulant☆ Track1 live phase-3 study: NCT07859111Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.

The 3 in phase 3 with the nearest primary completion, of 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Tetrodotoxin · Dogwood Therapeutics Inc. · Phase 2 main aimNCT06848348 Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain — primary endpoint: NRS Pain · 240 enrolled
  • 25 Jan 2027 est.suzetrigine · Vertex Pharmaceuticals Incorporated · Phase 3 main aimNCT06696443 Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) — primary endpoint: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) · 455 enrolled
  • 6 Apr 2027 est.suzetrigine · Vertex Pharmaceuticals Incorporated · Phase 3 main aimNCT07231419 Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy — primary endpoint: Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo · 734 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neuralgia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 2 open · Corticosteroids 1 open · NSAIDs 1 open · Opioids 18 · SNRIs 7

Coming up

96studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger. 8 (5%) take children under 18. 1 (1%) are for women only and 1 (1%) for men only; 12 (8%) take healthy volunteers.

Recruiting studies that take each age, of 153
AgeWomenMen
105 (3%)5 (3%)
18133 (87%)133 (87%)
30142 (93%)142 (93%)
40146 (95%)146 (95%)
50148 (97%)148 (97%)
65142 (93%)142 (93%)
75122 (80%)122 (80%)
8586 (56%)86 (56%)

Across all 1,102 studies, recruiting or not: 33% stop at 75 or younger and 17% at 65; 5% take children; 3% are for women only and 2% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuralgia studies take

Of 58 phase 2 interventional studies under Neuralgia, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo7–28 · 36 studies——
Phase 222 mo11–36 · 58 studies14 mo11–22 · 34 studies—
Phase 327 mo14–42 · 33 studies——
Phase 422 mo12–33 · 22 studies——
Interventional, no phase24 mo10–41 · 265 studies—24 mo11–41 · 247 studies
Observational21 mo12–55 · 88 studies—18 mo12–51 · 77 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,103. Browse all 1,103 → or search them.